PD-1 Antibody SHR-1210 Combined With Apatinib of First-line Treatment of Advanced Acral Melanoma
Status:
Unknown status
Trial end date:
2021-04-10
Target enrollment:
Participant gender:
Summary
the investigators launched this exploratory study to evaluate the objective response rate
(ORR) of SHR-1210 combined with apatinib mesylate in the first-line treatment of patients
with advanced acral melanoma.